Kornitzer Capital Management Inc. KS Acquires Shares of 80,275 DexCom, Inc. (NASDAQ:DXCM)

Kornitzer Capital Management Inc. KS bought a new position in DexCom, Inc. (NASDAQ:DXCM) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 80,275 shares of the medical device company’s stock, valued at approximately $9,961,000.

Several other institutional investors have also recently made changes to their positions in DXCM. Bartlett & CO. Wealth Management LLC bought a new stake in DexCom in the fourth quarter worth about $27,000. Valley National Advisers Inc. lifted its stake in shares of DexCom by 73.0% during the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after acquiring an additional 103 shares during the last quarter. Harbour Investments Inc. boosted its holdings in DexCom by 55.6% during the 3rd quarter. Harbour Investments Inc. now owns 336 shares of the medical device company’s stock valued at $31,000 after acquiring an additional 120 shares during the period. Atlas Capital Advisors LLC bought a new position in DexCom in the 2nd quarter valued at $33,000. Finally, MV Capital Management Inc. increased its stake in DexCom by 99.3% in the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after purchasing an additional 138 shares during the period. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Down 2.7 %

NASDAQ:DXCM traded down $3.59 during midday trading on Friday, reaching $130.71. 2,859,646 shares of the stock traded hands, compared to its average volume of 2,337,474. The stock has a market capitalization of $50.39 billion, a PE ratio of 99.78, a price-to-earnings-growth ratio of 2.31 and a beta of 1.20. DexCom, Inc. has a 12-month low of $74.75 and a 12-month high of $142.00. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.48 and a current ratio of 2.84. The business has a 50-day moving average of $129.55 and a two-hundred day moving average of $116.66.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 8th. The medical device company reported $0.50 EPS for the quarter, beating the consensus estimate of $0.43 by $0.07. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The firm had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.02 billion. During the same quarter in the prior year, the business posted $0.34 EPS. The business’s revenue for the quarter was up 26.9% compared to the same quarter last year. On average, equities analysts forecast that DexCom, Inc. will post 1.76 earnings per share for the current fiscal year.

Insider Activity at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 81,007 shares of the business’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the sale, the chief executive officer now owns 333,526 shares of the company’s stock, valued at approximately $44,479,027.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other DexCom news, CEO Kevin R. Sayer sold 81,007 shares of DexCom stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the completion of the sale, the chief executive officer now owns 333,526 shares of the company’s stock, valued at approximately $44,479,027.36. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Jereme M. Sylvain sold 3,363 shares of the business’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total value of $392,562.99. Following the sale, the chief financial officer now owns 71,142 shares in the company, valued at approximately $8,304,405.66. The disclosure for this sale can be found here. Insiders sold 189,375 shares of company stock valued at $25,530,859 in the last three months. 0.41% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on DXCM. UBS Group boosted their target price on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Raymond James raised their target price on shares of DexCom from $147.00 to $151.00 and gave the stock a “strong-buy” rating in a research report on Tuesday, January 23rd. Royal Bank of Canada assumed coverage on DexCom in a report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price target for the company. Citigroup raised their price objective on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a report on Wednesday, April 3rd. Finally, StockNews.com upgraded DexCom from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Two investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $141.40.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.